Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 246 participants.
Also called NCT04530617
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 246 participants
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Registry
-
NCT04530617
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Mexico
- Registry status
- Terminated
Technical summary
Registry record NCT04530617. Randomized; triple masking; primary purpose treatment. Start 2020-10-05 (actual); primary completion 2021-06-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients
- Condition
- Covid19
- Condition
- Diabetes
- Condition
- Hypertension
- Condition
- Obesity
- Intervention (Drug)
- Camostat Mesilate
- Intervention (Drug)
- Artemisia Annua Leaf
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Record details
- Record id
cardio:ct-nct04530617- Content hash
cc12851c72def0ea83fed928eff683ac20f961dfab38b0dbc92ec135cd40f800